Boise State University

ScholarWorks
Biology Faculty Publications and Presentations

Department of Biological Sciences

3-10-2022

Nonhistone Lysine Methylation as a Protein Degradation Signal
Nicholas A. Lehning
Boise State University

Brad E. Morrison
Boise State University

Publication Information
Lehning, Nicholas A. and Morrison, Brad E. (2022). Nonhistone Lysine Methylation as a Protein
Degradation Signal. Journal of Chemistry, 2022, 1969299. https://doi.org/10.1155/2022/1969299

Hindawi
Journal of Chemistry
Volume 2022, Article ID 1969299, 7 pages
https://doi.org/10.1155/2022/1969299

Review Article
Nonhistone Lysine Methylation as a Protein Degradation Signal
Nicholas A. Lehning
1
2

1

and Brad E. Morrison

1,2

Biomolecular Ph.D. Program, Boise State University, Boise 83725, ID, USA
Department of Biological Sciences, Boise State University, Boise 83725, ID, USA

Correspondence should be addressed to Brad E. Morrison; bradmorrison@boisestate.edu
Received 13 January 2022; Accepted 24 February 2022; Published 10 March 2022
Academic Editor: Mohd. Sajid Ali
Copyright © 2022 Nicholas A. Lehning and Brad E. Morrison. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Protein degradation is a fundamental feature of cellular life, and malfunction of this process is implicated in human disease.
Ubiquitin tagging is the best characterized mechanism of targeting a protein for degradation; however, there are a growing
number of distinct mechanisms which have also been identiﬁed that carry out this essential function. For example, covalent
tagging of proteins with sequestosome-1 targets them for selective autophagy. Degradation signals are not exclusively polypeptides
such as ubiquitin, NEDD8, and sequestosome-1. Phosphorylation, acetylation, and methylation are small covalent additions that
can also direct protein degradation. The diversity of substrate sequences and overlap with other pleotrophic functions for these
smaller signaling moieties has made their characterization more challenging. However, these small signals might be responsible
for orchestrating a large portion of the protein degradation activity in the cell. As such, there has been increasing interest in lysine
methylation and associated lysine methyltransferases (KMTs), beyond canonical histone protein modiﬁcation, in mediating
protein degradation in a variety of contexts. This review focuses on the current evidence for lysine methylation as a protein
degradation signal with a detailed discussion of the class of enzymes responsible for this phenomenon.

1. Introduction
Protein degradation is a critical function for regulating
signaling and removal of dysfunctional or misfolded proteins. There are two canonical methods by which this occurs.
The ubiquitin/proteasome system (UPS) is the most welldescribed while the second is autophagy, which can be
further distinguished as macroautophagy, microautophagy,
or chaperone-mediated autophagy. The importance of these
processes is illustrated by protein aggregation and other
maladies that occur subsequent to the failure of protein
turnover machinery. Many diseases feature protein aggregation as their hallmark, and it is reasonable that this could
result from aberrant protein degradation as these are often
shown to be linked [1, 2].
Similarly, protein degradation during cellular diﬀerentiation is the key to the changing of cellular identity. This
process, though, requires that the cell target large numbers of
proteins for degradation as global proteome turnover occurs. This dictates a few key requirements that would be

necessary for an eﬀective global degradation signal including
that it be small and energetically inexpensive, unrestricted by
sequence, and paired with an enzyme whose dysfunction is
linked to disorders that include aberrant cell diﬀerentiation.
One potential solution to the problem is lysine methylation.
Nonhistone lysine methylation is a post-translational
modiﬁcation that has garnered increased attention over
recent years. While histone methylation has been wellstudied since its discovery in 1964, nonhistone substrates for
lysine methylation have begun to be identiﬁed of late [3, 4].
The enzymes responsible for the methylation of lysine
residues are termed lysine methyltransferases (KMTs), and
those that remove them are termed lysine demethylases
(KDMs). The amine group that is characteristic of lysine
residues can accept up to three methyl groups (Figure 1).
This is an interesting alteration to the chemical state of lysine
in that the positively charged side chain accepts between one
and three hydrophobic groups that reside in close proximity
to the positive charge. This creates a diametric epitope that
could be readily discriminated by the cell. In fact, a variety of
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Figure 1: Potential methylation states of lysine. Generation of these three species is catalyzed by lysine methyltransferases (KMTs) and
lysine demethylases (KDMs) through the addition and removal of methyl groups, respectively.

proteins that can recognize methylated lysines have been
identiﬁed [5–7]. These methyl-lysine-binding proteins are
speciﬁc to the number and position of methyl groups added
to a lysine residue, making each its own distinct signal. The
addition of methyl groups to lysine residues has been shown
to impact protein-protein interactions, protein-DNA interactions, and protein stability [8–13]. A number of enzymes exist that have been shown to perform mono-, di-,
and trimethylations of lysine residues (Table 1). While most
of these enzymes are canonically histone methylators, many
of them have overlapping function as nonhistone methylators as well [48].

2. Methylation of Nonhistone Proteins
Investigation of proteome methylation has generally been
centered on histone modiﬁcation. This is likely due to the
challenges associated with the identiﬁcation of methylation
events using common methods (e.g., western blotting).
Methylation results in small changes to mass and no alteration of charge making them diﬃcult to observe. This
feature also reduces the numbers of antibody reagents that
can speciﬁcally recognize this post-translational modiﬁcation (PTM). When considering nonhistone proteins, the
relative low abundance of methylations when compared to
histone methylation also presents a challenge. Enrichment
techniques have allowed for the application of a few analytical methods for identifying methylated proteins. Mass
spectrometry is the most widely used method because when
paired with enrichment steps, it can identify not only the
presence of methylation but also the nature of methylation
(mono-, di-, or tri-) [49, 50]. Chemical enrichment has also
enabled the application of aﬃnity tagging for labeling lysine
methyltransferase substrates (e.g., bioorthogonal proﬁling
and click labeling) [51–53]. These techniques have led to the
identiﬁcation of a number of nonhistone lysine methyltransferase targets.
Nonhistone lysine methylation is a relatively new ﬁeld,
but it is fast becoming increasingly apparent that this post-

translational modiﬁcation plays a role in cell signaling,
particularly within the context of cancer [29, 54]. A central
example of this is p53. The tumor suppressor has recently
been identiﬁed as a substrate for SETD7-mediated methylation [55]. It is important to note that p53 methylation by
SETD7, speciﬁcally at K372, prevents the addition of other
PTMs that inhibit p53 activity [56–59]. Methylation of p53 is
site- and context-speciﬁc with regard to protein function
and stability. Both methylation by SETD7 [55] and demethylation by KDM4A [60] alter p53 stability.
Another protein exhibiting regulation by regulatory
methylation is β-catenin. β-catenin is involved in a variety
of cellular activities including proliferation, while its
dysfunction has been well characterized in tumorigenesis.
Methylation of β-catenin has eﬀects on stability, translocation, and activity as a transcriptional regulator [61–63].
Other nuclear targets of nonhistone lysine methylation
include RB transcriptional corepressor 1, E2F1, HIF1,
reptin, FOXO3, NFΚB complex components, and ARTD1
[64–70]. In addition, there have been several other nuclear
proteins (nonhistone) identiﬁed as targets that play a wide
variety of roles in within the cell [71]. Adding complexity is
the fact that lysine methylation occurs across the three
states: mono-, di-, and trimethylation. Therefore, understanding these individual PTMs in the context of speciﬁc
signaling events as they relate to protein degradation could
inform novel therapeutic approaches.

3. Lysine Methyltransferases
There is a wide spectrum of enzymes capable of catalyzing
the addition of methyl groups to lysine residues. As previously discussed, the majority of them perform their
function on histones, but many have nonhistone substrates.
In line with this notion, the vast majority of these proteins
are localized to the nucleus. A select few, though, are localized to, and active in the cytosol.
Lysine methyltransferases exist in one of two superfamilies: the SET-domain containing superfamily and the
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Table 1: Enzymes with lysine-methylating activity. The enzymes in
the SET-domain family and the 7β-strand family that are active in
lysine methylation. Also listed are the known methylation states
each enzyme is capable of producing. Many lysine-methylating
enzymes have disputed function, and the 7β-strand family is still
being investigated in eukaryotes.
Gene name
EZH1/KMT6B
EZH2/KMT6A
EHMT1/
KMT1D
EHMT2/
KMT1C
NSD1/KMT3B
NSD2
NSD3
SETD1A
SETD1B
SETD4
SETD6
SETD7
SETD9
KMT5A
SMYD2
SMYD3
SMYD5
SETMAR
ASH1L/
KMT2H
DOT1L
MLL
MLL2
MLL3
MLL4
MLL5
SUV39H1

Superfamily
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain
SETdomain

Lysine methylation

Reference

Mono, di, tri

[14, 15]

Mono, di, tri

[16]

Mono, di

[17]

Mono, di, tri

[18]

Mono, di

[19]

Mono, di

[20]

Mono, di

[20]

Mono, di, tri

[21]

Mono, di, tri

[22]

Mono, di

[23]

Mono

[24]

Mono, di

[25]

Mono, di

[25]

Unknown

[26]

Mono, di

[27, 28]

Mono, di, tri

[29]

Unknown

[30]

Mono, di, tri

[30]

Di, tri

[28]

Mono, di, tri

[31]

Mono, di, tri

[32]

Mono, di, tri

[33]

Mono, di, tri

[31]

Mono, di, tri

[34]

Unknown

[35]

Di, tri

[36]

Table 1: Continued.
Gene name
SUV39H2
SUV420H1
SUV420H2
PRDM2-17
CAMKMT
VCPKMT
EEF1-AKMT1
EEF2KMT
METTL10
METTL20
METTL21A
METTL22

Superfamily
SETdomain
SETdomain
SETdomain
SETdomain
7β-strand
7β-strand
7β-strand
7β-strand
7β-strand
7β-strand
7β-strand
7β-strand

Lysine methylation

Reference

Di, tri

[37]

Di, tri

[38]

Di, tri

[38]

Disputed or
unknown
Tri
Tri
Tri
Tri
Mono, di, tri
Tri
Tri
Unknown

[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]

7β-strand enzymes. The SET-domain superfamily (55 human enzymes) functions primarily on histones with some
members acting on both histone and nonhistone proteins.
However, only a markedly small portion of function is on
nonhistone proteins. Near half of the SET-domain members
are orphans (substrates unknown). The 7β-strand superfamily contains 125 enzymes and is not lysine-speciﬁc nor is
protein-speciﬁc. This group as a whole can methylate several
diﬀerent amino acids as well as nucleic acids [72].
SET-domain KMTs contain a four-motif conserved
domain that facilitates catalysis. These domains are twisted
into knot-like β-sheets, and it is thought that these “pseudoknots” are key to determining substrate speciﬁcity [73].
SET-domain lysine methyltransferases that are able to
perform nonhistone methylations are EZH1, EZH2,
EHMT1, EHMT2, NSD1, SETD3, SETD4, SETD6, SETD7,
SETD8, SMYD2, SMYD3, SMYD5, and SETMAR. It is
worthwhile to point out that a few of these (SMYD3, SETD3,
and SETD4) not only have nuclear nonhistone targets but
also nonhistone targets in the cytosol [74–76]. This is notable
due to the fact that KMTs are largely associated with the
nuclear localization and activity. This also supports a widespread role of lysine methylation as a degradation signal
since most of the cellular protein content is housed in the
cytoplasm, making non-nuclear KMTs needed for targeting
large swaths of the proteome.
SET-domain KMTs have been shown to be clinically
relevant. For example, ASH1L is linked to fascioscapulohumeral muscular dystrophy [77]. MLL (or
KMT2a), SUV420H1 (KMT5b), and MLL5 (KMT2e) have
all been linked to autism [78–80]. Numerous families including the PRDMs, SETDs, and SMYDs contain members
with associations to a wide variety of cancers. The clinical
signiﬁcance of SET-domain KMTs along with their ability to
methylate both histone and nonhistone targets in the nucleus and the cytosol make them an important line of future
inquiry as well as potential therapeutic targets.
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4. Evidence for Lysine Methylation as a
Degradation Signal
Lysine methylation is capable of inducing numerous eﬀects
depending on the site and the protein. We have discussed
changes to protein-protein interactions as well as changes to
protein-DNA interactions. Perhaps the most interesting
downstream eﬀect of lysine methylation is destabilization of
the protein target. There are instances where methylations at
diﬀerent sites can either induce degradation or even inhibit
ubiquitination and, thereby, increase stability [81]. Both the
positive and negative regulation has been demonstrated to
occur, as well as the three diﬀerent methylation states having
diﬀerential eﬀects.
DNMT1, a major DNA methyltransferase, exhibits both
positive and negative regulation of stability by lysine
methylation. If the K142 residue of DNMT1 is methylated,
the recognition complex determines the outcome. PHF20L1
contains an MBT domain that can bind to this methylation
side and prevent ubiquitin ligases from acting, leading to
inhibition of the degradation process [82]. Conversely, if
L3MBTL3 binds the same methylation site, ubiquitin ligases
are recruited and DMNT1 is degraded [83]. This careful
interplay of lysine methylation and recognition proteins
determines the fate of DNMT1 and may represent broader
paradigm for the investigation of other proteins that may
have similar duality.
Many other proteins have been reported to be degraded
upon lysine methylation. FOXO1 is a well-studied example.
It has been shown that methylation of FOXO1 by G9a
(EHMT2) leads to increased interaction with the E3 ubiquitin ligase SKP2 while also decreasing the protein’s stability
[65]. Similarly, lysine methylation has shown to have negative eﬀects on the stability of proteins such as p53 and AR
[65, 84]. The NFΚB complex component Rel A is degraded
in response to methylation by Set9 [70]. Another protein
whose degradation is mediated by lysine methylation is the
transcription factor E2F1. Multiple post-translational
modiﬁcations act in tandem on E2F1 to stimulate degradation. When K185 is methylated, it prevents the acetylation
and phosphorylation at a few positions far from K185 while
inducing ubiquitination and, in turn, degradation [65].
These changes in stability are widely accepted to originate
from one of a few sources including disruption of chargestabilized regions of the protein leading to misfolding or
unfolding, recruitment of unfolding chaperones, or direct
proteasome targeting.

5. Summary and Future Perspectives
As our knowledge base regarding KMTs and lysine methylation expands, so does the breadth of roles this PTM plays
within the cell. It has become clear the lysine methylation is
not limited to histones, nor is it limited to nuclear roles. This
is evidence that lysine methylation can instigate a multitude
of cellular eﬀects beyond the assembly of heterochromatin.
In particular, target destabilization is an important function
with growing interest. In considering the potential for lysine
methylation to constitute a degradation signal, the current
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understanding of the PTM’s ability to induce misfolding or
direct proteasome targeting becomes increasingly notable.
Lysine methylation satisﬁes the qualiﬁcations of being both
unbound by amino acid sequence, unlike pathways relying
upon consensus sequences, and relatively small and energetically inexpensive to deliver, unlike ubiquitination. It is
possible that protein destabilization and/or recruitment of
E3 ligases is the mechanism by which lysine methylation acts
as a panproteomic degradation signal. While this line of
thinking is interesting, it has yet to be reported. As discussed
in this review, there have been major advances in our understanding of nonhistone lysine methylation. Still, questions remain as to whether alterations to KMTs associated
with nonhistone methylation lead to aberrant protein aggregation on a broader scale or with direct human disease
relevance. Such evidence would directly signify the physiological importance of protein degradation through lysine
methylation.
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